• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

The ZF2001 vaccine is safe and effective at preventing COVID-19 in adults

byDavid XiangandKiera Liblik
June 18, 2022
in Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The ZF2001 vaccine significantly reduces the risk of contracting symptomatic coronavirus disease 2019 (COVID-19) as compared to a placebo control.

2. Those in the ZF2001 vaccine group also reported significantly lower rates of severe-to-critical COVID-19 infection as compared to the placebo group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The ZF2001 vaccine contains a dimeric form of the receptor-binding domain of the SARS-CoV-2 spike protein. It has been demonstrated to have high efficacy in preventing infection with extremely transmissible strains of COVID-19 such as the delta and omicron variants. The ZF2001 vaccine also requires a less stringent cold-chain transport and storage protocol than previously approved vaccines. This means that it could have increased accessibility for global distribution. However, there is a gap in knowledge as to understanding its efficacy and safety profile in adults as measured during periods of high prevalence of the delta variant. The present study found that the ZF2001 vaccine has limited associated adverse events and is very effective at preventing both symptomatic and severe-to-critical COVID-19 for at least six months following full vaccination series in adults. This study was limited by factors such as having mostly Asian participants in their trial and limited recruitment of participants aged 60 years or older. Additionally, the efficacy of the vaccine against asymptomatic infections was not evaluated. Nevertheless, the findings are significant as they demonstrate that the ZF2001 vaccine is a viable alternative to preventing symptomatic and moderate-to-severe COVID-19 in adults to less stable vaccines which are currently approved for widespread use.

Click to read the study in NEJM

Relevant Reading: Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant

RELATED REPORTS

Oral vancomycin may be effective for pouchitis in inflammatory bowel disease

2 Minute Medicine Rewind July 7, 2025

Trimethoprim-sulfamethoxazole during pregnancy does not reduce risk of prematurity

In-Depth [randomized control trial]: This randomized control trial was conducted at 31 clinical centers in Uzbekistan, Indonesia, Pakistan, Ecuador, and China, with 28,873 total participants. Patients who were 18 years of age or older and able to provide written, informed consent were eligible for the study. Patients who had a history of COVID-19, previous COVID-19 vaccination, or a history of congenital or acquired immune deficiency or autoimmune deficiency were excluded from the study. Patients in the study were randomized to receive either three placebo shots or three ZF2001 vaccine doses. The primary outcome measured was real-time PCR-confirmed symptomatic COVID-19 occurring at least seven days after the third dose. Outcomes in the primary analysis were assessed via Poisson regression models and according to the large-sample hypothesis of Poisson distribution. Based on the analysis, confirmed symptomatic COVID-19 was seen in 158 of the 12,625 participants in the ZF2001 group and in 580 of the 12,568 participants in the placebo group, for a vaccine efficacy of 75.7% (95% Confidence Interval [CI], 71 to 79.8). For severe-to-critical COVID-19, the vaccine efficacy was 87.6% (95% CI, 70.6 to 95.7). Death due to COVID-19 occurred in two participants in the ZF2001 group and in 12 participants in the placebo group, demonstrating a vaccine efficacy of 86.5% (95% CI, 38.9 to 98.5) against mortality. Additionally, vaccine efficacy was 76.1% (95% Ci, 70 to 81.2) against infection with the delta variant. The incidence of adverse events and serious adverse events was not significantly different between the two groups. Overall, this study demonstrates that the ZF2001 COVID-19 vaccine is effective and safe in adults for preventing symptomatic and moderate-to-severe COVID-19.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: COVID-19COVID-19 Vaccineinfectious diseasepublic healthZF2001 vaccine
Previous Post

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Next Post

2 Minute Medicine Rewind June 20, 2022

RelatedReports

Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Oral vancomycin may be effective for pouchitis in inflammatory bowel disease

July 10, 2025
Weekly Rewinds

2 Minute Medicine Rewind July 7, 2025

July 10, 2025
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Infectious Disease

Trimethoprim-sulfamethoxazole during pregnancy does not reduce risk of prematurity

June 9, 2025
Government-funded initiatives provide important supports to low-income HIV patients
Infectious Disease

Second-line TAF-based ART improves viral suppression in pediatric HIV

June 4, 2025
Next Post
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

2 Minute Medicine Rewind June 20, 2022

Provision of medically-tailored meals linked with lower admissions and medical spending

Gut microbiota signatures of long-term and short-term plant-based dietary pattern and cardiometabolic health

Mortality after trauma increasingly due to preexisting conditions

Sotrovimab reduces the severity of COVID-19 progression

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.